Americas

The latest science and research on antibody engineering, design and selection diving into critical topics including immuno-oncology, cellular engagers, miniproteins, the Fc region, cancer therapy, novel bi-specifics/multispecifics and much more!

Combining FDA, notified body and industry perspectives to shape the future of medical device regulations

Immuno-Oncology (IO) 360° takes a strategic look at the business and scientific aspects of Immuno-Oncology.  With significant in-put from Lead Advisors Dr. Axel Hoos (former CEO of Scorpion Therapeutics) and Dr. James Gulley (NCI,) the conference examines the current landscape, and reports on the latest advancements in IO to improve and accelerate clinical trials. The audience is comprised of roughly 500 top executives at Pharma companies and Biotechs, as well as the financial community, consultants and leading research organizations in the field of Immuno-Oncology.  

The 2022 ISPE Annual Meeting & Expo will usher in a revitalized focus on excellence, modernization, and harmonization in pharmaceutical science and manufacturing across the globe, offering pharma professionals the opportunity to engage in industry-critical conversations. A comprehensive education program provides attendees with technical sessions on the latest developments in supply chain, operations, facilities, equipment, information systems, product development, production systems, quality systems, regulatory guidance and cutting-edge industry innovations. This signature event draws pharmaceutical and biopharmaceutical professionals at all levels of the industry from emerging leaders to the most senior executives in drug manufacturing, supply chain, devices and equipment and services, and global regulatory agencies. The conference Partner Showcase presents a large offering of the latest technologies and services for the pharmaceutical industry.

An important event in the global Life Sciences. Attended by >500 companies.

Recognized as one of the top 50 medical meetings by HCEA, Digestive Disease Week® (DDW) is the world’s largest gathering of physicians, researchers and industry in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery.

DCAT Week is not a Trade Show. It is a multifaceted event where DCAT Member Companies have the opportunity to reserve meeting space through the DCAT organization to conduct high-level, private, strategic meetings with customers and suppliers.

Returning in 2022, the Tumor Myeloid-Directed Therapeutics Summit is the only industry-focused meeting dedicated to unlocking novel therapeutic potential through the myeloid compartment.  This is your ultimate forum to identify, validate, and clinically progress myeloid targets to expand the oncologists toolkit and realize better responses by engaging myeloid anti-tumor function. Designed for experts working directly on myeloid-directed therapies, and those in adjacent immuno-oncology fields, from cell therapy to checkpoint and engager development. If you’re scratching your head in attempt to enhance efficacy in solid tumors and overcome barriers in the microenvironment, this is your 500-foot view of the intricate pathways, interactions, and novel target development in the tumor microenvironment. Deep-dive into myeloid biology, guided by 27+ industry Gurus from the likes of Pionyr Immunotherapeutics, Gilead Sciences, Merck, Verseau Therapeutics, Carisma Therapeutics, Pfizer and many more. With targets such as TREM1 and TREM2 making waves in the clinic, analysis of CD47 candidates back-translating to next-generation therapies, and novel dendritic cell candidates such as FTL3 in development, this 3-day myeloid extravaganza is unmissable for anyone looking to unlock better therapeutic potential through the myeloid compartment.

As Biopharma turn their focus to autoimmune drug development, there has been an explosion of interest and investment into Treg directed therapies. Promising proof-of-concept data and early clinical read outs have fueled further hype, and the industry now looks to demonstrate efficacy. The 4th Treg Directed Therapies Summit returns to Boston this May, bigger and better than ever before, boasting 2 tracks of unparalleled content to cater to cell-based, and non-cell-based experts alike. This is the only industry-focused meeting designed to bridge the gap between early discovery through clinical development of cell-based and non cell-based Treg directed therapies to provide efficacious treatments for patients globally. With 3 days of unrivalled content spanning the fundamental biology of Tregs, optimizing early drug development, and streamlining clinical development, join with your team to:Optimize stable expansion of Tregs to maintain function to elicit durable responses
Decode Treg interactions to optimize the mechanism of actions and inform biomarker development
Rationalize activation, formulation & delivery strategy to induce antigen specific tolerance
Supercharge CMC strategy to drive the modulation of antigen-specific responses to yield maximum clinical efficacy

From preclinical conversations to the latest developments in streamlined manufacturing this year’s meeting will be the most comprehensive guide for addressing the unique challenges of TIL development to bolster and strengthen your pipelines to achieve your 2022/23 milestones. With 20+ world-class speakers and over 100 senior attendees from around the globe, join the largest community of TIL-targeted drug development experts for a deep dive into clinical development progress, lessons learnt and novel strategies to maximize TIL-targeting to recognize and capitalize on this outstanding approach in adoptive cell therapy! Now is the time to leverage actionable insights to ensure you are set to capitalize on this achieve significant expansion in your development.